24
Oct
2022
Tag: pharma
10
Oct
2022
Bionest
Are the Blues Ending for Bluebird?
Gene therapy developer bluebird bio may be turning a corner, with recent FDA approvals for two of its rare disease therapeutics.
19
Sep
2022
Bionest
ASCO 2022 – Part 1: Redefining Breast Cancer Classification and Treatment
An important new development in breast cancer greatly expands the number of patients who might benefit from HER2-targeting treatment, as shared at ASCO 2022
6
Sep
2022
Bionest
Potential Game Changers in Diabetes and Obesity
Is metformin on the way out as a first-line therapy for type 2 diabetes, to be replaced by tirzepatide? We examine new treatments for diabetes and obesity.
25
Jul
2022
Bionest
Big Tech’s Foray in Healthcare
By bringing its unique strengths to specific health problems, can Big Tech play a larger role in many facets of healthcare?
25
Apr
2022
Bionest
Biosimilars on the Rise, Spurring Company Integration and Consolidation
From one to 34: Biosimilars are on the rise. How will it affect the pharmaceutical market for companies and consumers?
28
Mar
2022
Bionest
ASH 2021 Update: Part 2
A look at new hematology therapy developments for hemophilia, beta thalassemia and sickle cell disease presented at ASH 2021.
14
Mar
2022
Bionest
ASH 2021 Update: Part One
Are anti-CD38 antibodies & CAR-T treatments living up to their promise for multiple myeloma patients? We examine clinical trial results shared at ASH2021
28
Feb
2022
Bionest
Trends to Watch in 2022 after the 40th Annual JPM Conference
Fewer blockbuster M&A announcements, more early-stage partnerships & acquisitions. We examine trends for 2022 that emerged at JPM
31
Jan
2022